All In Biotech

BLA 761039 · Coherus Biosciences INC

Udenyca

Pegfilgrastim-Cbqv · Injection · Leukocyte Growth Factor

Last checked: Nov 20, 2026Latest source record: Dec 22, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2018

Nov 2, 2018

Approved uses

4

Original approval plus efficacy supplements

Registered trials

400

72 Phase 3, 30 recruiting

FAERS reports

1,434

291 serious, 130 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Apr 23, 2026.

UDENYCA is a leukocyte growth factor indicated to Decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia. ( 1.1 ) Increase survival in patients acutely exposed to myelosuppressive doses of radiation (Hematopoietic Subsyndrome of Acute Radiation Syndrome). ( 1.2 ) Limitations of Use UDENYCA is not indicated for the mobilization of peripheral blood progenitor cells for hematopoietic stem cell transplantation. 1.1 Patients with Cancer Receiving Myelosuppressive Chemotherapy UDENYCA is indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia [see Clinical Studies ( 14.1 )] . Limitations of Use UDENYCA is not indicated for the mobilization of peripheral blood progenitor cells for hematopoietic stem cell transplantation. 1.2 Patients with Hematopoietic Subsyndrome of Acute Radiation Syndrome UDENYCA is indicated to increase survival in patients acutely exposed to myelosuppressive doses of radiation [see Dosage and Administration ( 2.2 ) and Clinical Studies ( 14.2 )] .

Mechanism: Pegfilgrastim products are colony-stimulating factors that act on hematopoietic cells by binding to specific cell surface receptors, thereby stimulating proliferation, differentiation, commitment, and end cell functional activation.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • UDENYCA · PEGFILGRASTIM-CBQV 6MG/0.6ML · INJECTABLE, INJECTION · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Pegfilgrastim" as an intervention, any sponsor and status, largest first.

All 400 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • device malfunction915
  • no adverse event715
  • product dose omission issue159
  • death99
  • accidental exposure to product39
  • device failure38
  • product label confusion36
  • neutrophil count decreased30
  • device leakage24
  • bone pain21
  • nausea20
  • white blood cell count decreased19

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
201978
2020119
202168
202255
202330
2024272
2025358
2026454

Recalls

1 FDA enforcement reports for this application.

  • Jan 16, 2026 · Class I · Ongoing

    Temperature Abuse. 116 cartons with specific serial numbers of Lot 2199821, were stored incorrectly in a controlled room temperature environment instead of the required refrigerated environment.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Udenyca (PEGfilgrastim-Cbqv)

2024 spending

$13.4M

Beneficiaries

962

2,873 claims

Per beneficiary

$13,959

$6,598.61 per unit

View as table
YearSpending
2020$8,343,087
2021$8,381,827
2022$6,204,814
2023$7,543,946
2024$13,428,171

Part B: Udenyca* (Pegfilgrastim-Cbqv*) · HCPCS Q5111

2024 spending

$91.0M

Beneficiaries

16,032

52,151 claims

Per beneficiary

$5,677

2024 ASP limit $141.75 per unit

View as table
YearSpending
2020$228,110,103
2021$160,042,880
2022$88,617,866
2023$67,282,230
2024$91,015,072

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 308 on PubMed

Sponsor: Coherus Biosciences INC

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.